Kronos shelves sole remaining clinical asset over neurological side effects – Fierce Biotech

The San Mateo, California-based biotech said it had made the decision to halt work on istisociclib after reviewing safety data from an ongoing …

Continue

Do you trust this headline?

Based on recent headline ratings, 84% of this readership currently trusts the local media, which has an average score of 83% regionally and is currently trending positivepositive.

84%

Media Trust Score

Read All

In

News